Rexgenero readies cell therapy for Critical Limb Ischemia Phase III

February 8, 2017 Christoph Graener

Founded as recently as 2014, Rexgenero is poised to start two Phase III trials of its lead candidate Rexmyelocel-T (REX-001) in patients with Critical Limb Ischemia. CEO Dr. Joe Dupere tells Mike Ward, Informa Pharma Intelligence’s insights global director of content, that the London-based cell therapy company is seeking new investors and potential partners for Asian and Middle Eastern markets.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Joe Dupere – CEO, Rexgenero Ltd

Previous Article
Mounting uncertainty threatens research and innovation in medicines
Mounting uncertainty threatens research and innovation in medicines

Regulatory reforms, political upheavals and proposed cuts to research funding create an uncertain and incre...

Next Article
VIDEO: Innovation in an uncertain world
VIDEO: Innovation in an uncertain world

How are cutting-edge biotech companies trying to compete in a global marketplace dealing with drug-price an...